Genentech's GA101 meets in Phase III trial for CLL

Genentech Inc. said that obinutuzumab ( GA101) plus chlorambucil chemotherapy met the primary endpoint of improving progression-free survival (PFS) vs. chlorambucil alone in Stage 1 of the three-arm Phase III CLL11 trial to treat chronic lymphocytic leukemia (CLL). Stage 1 is evaluating obinutuzumab plus chlorambucil compared to chlorambucil alone, while Stage 2 is evaluating obinutuzumab plus chlorambucil compared to Rituxan rituximab plus chlorambucil. The unit of Roche (SIX:ROG; OTCQX:RHHBY) said the data will be submitted to U.S. and European regulatory authorities for potential approval, but declined to provide details. ...